University of Bristol researchers compile new clinical guidance for uveitis

Researchers from the University of Bristol have developed new clinical guidance for the diagnosis and management of uveitis.

The guidance was compiled after the scientists reviewed more than 2900 published studies on the condition.

Writing in JAMA, researchers highlighted that corticosteroid eyedrops should be a first-line treatment for non-infectious anterior uveitis, while disease-modifying antirheumatic drugs should be a first-line therapy for posterior non-infectious uveitis.

The researchers outlined that biologics such as adalimumab are a second-line treatment for patients with inflammation refractory to treatment. Uveitis caused by systemic infection should be treated with antimicrobials.

“Local or systemic steroids may be used depending on the severity of uveitis and the specific microorganism,” the authors stated.

Lead author, University of Bristol’s Dr Panayiotis Maghsoudlou highlighted: “Diagnosing and treating uveitis is challenging due to the varying presentation of multiple subtypes, each with distinct underlying causes and responses to treatment. This variability complicates both early recognition and the selection of appropriate treatment strategies, as different forms of the disease require tailored approaches.”

Senior author, Bristol Medical School’s Professor Andrew Dick shared that while uveitis is a leading cause of preventable blindness, it is underdiagnosed and undertreated.

“Our study has identified the most effective treatments depending on the type and cause of the inflammation. By tailoring treatment approaches, we can significantly decrease the likelihood of vision loss, which is the most serious potential outcome of untreated eye inflammation,” he said.